Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA-Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–91.

Article  PubMed  PubMed Central  Google Scholar 

Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun. 2022;42(10):937–70.

Article  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.

Article  CAS  PubMed  Google Scholar 

Xia LL, Liu YY, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. 2019;24(Suppl 1):S31–41.

Article  PubMed  PubMed Central  Google Scholar 

Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(98):1623–40.

Article  CAS  PubMed  Google Scholar 

Patel SA, Weiss J. Advances in the treatment of non-small cell lung cancer: immunotherapy. Clin Chest Med. 2020;41(2):237–47.

Article  PubMed  Google Scholar 

Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xing Y, Chand G, Liu C, Cook GJR, O’Doherty J, Zhao L, et al. Early phase I study of a 99mTc labeled anti-PD-L1 sdAb in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer. J Nucl Med. 2019;60(9):1213–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang S, Qin C, Hu H, Liu T, He Y, Guo H, et al. Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells. 2022;11(3):320.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2(1):46–54.

Article  PubMed  PubMed Central  Google Scholar 

Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–62.

Article  CAS  PubMed  Google Scholar 

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24(12):1852–8.

Article  CAS  PubMed  Google Scholar 

Nimmagadda S. Imaging PD-L1 expression in melanoma brain metastases. J Nucl Med. 2022;63(6):897–8.

Article  PubMed  PubMed Central  Google Scholar 

Smit J, Borm FJ, Niemeijer AN, Huisman MC, Hoekstra OS, Boellaard R, et al. PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced-stage non-small cell lung cancer. J Nucl Med. 2022;63(5):686–93.

CAS  PubMed  Google Scholar 

Liu Q, Jiang L, Li K, Li H, Lv G, Lin J, et al. Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers. Cancer Immunol Immunother. 2021;70(6):1721–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mishra A, Kumar D, Gupta K, Lofland G, Sharma AK, Banka DS, et al. Gallium-68-labeled peptide PET quantifies tumor exposure of PD-L1 therapeutics. Clin Cancer Res. 2023;29(3):581–91.

Article  CAS  PubMed  Google Scholar 

Zhu S, Liang B, Zhou Y, Chen Y, Fu J, Qiu L, et al. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy. Eur J Nucl Med Mol Imaging. 2024;51(3):625–40.

Article  CAS  PubMed  Google Scholar 

Sun S, Ding Z, Yang X, Zhao X, Zhao M, Gao L, et al. Nanobody: a small antibody with big implications for tumor therapeutic strategy. Int J Nanomed. 2021;16:2337–56.

Article  Google Scholar 

Lecocq Q, De Vlaeminck Y, Hanssens H, D’Huyvetter M, Raes G, Goyvaerts C, et al. Theranostics in immuno-oncology using nanobody derivatives. Theranostics. 2019;9(25):7772–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu M, Li L, Jin D, Liu Y. Nanobody-A versatile tool for cancer diagnosis and therapeutics. Wiley Interdiscip Rev-Nanomed Nanobiotechnol. 2021;13(4):e1697.

Article  CAS  PubMed  Google Scholar 

Su J, Liu X, Guo S, Zhang J, Wei X, Li X. Nanobodies: a new potential for prostate cancer treatment. J Cancer Res Clin Oncol. 2023;149(9):6703–10.

Article  PubMed  Google Scholar 

Mitran B, Güler R, Roche FP, Lindström E, Selvaraju RK, Fleetwood F, et al. Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. Theranostics. 2018;8(16):4462–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Wang C, Huang M, Qin S, Zhao J, Sang S, et al. Pilot study of a novel nanobody 68Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells. Eur J Nucl Med Mol Imaging. 2022;49(13):4394–405.

Article  CAS  PubMed  Google Scholar 

Ge S, Wang C, You X, He H, Zhang B, Jia T, et al. Imaging and monitoring HER2 expression in tumors during HER2 antibody-drug conjugate therapy utilizing a radiolabeled site-specific single-domain antibody probe: 68Ga-NODAGA-SNA004-GSC. J Med Chem. 2024;67(15):12855–67.

Article  CAS  PubMed  Google Scholar 

Gong J, Zhao L, Yang J, Zhu M, Zhao J. [99mTc]Tc-labeled plectin-targeting peptide as a novel SPECT probe for tumor imaging. Pharmaceutics. 2022;14(5):996.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wong NC, Cai Y, Meszaros LK, Biersack HJ, Cook GJ, Ting HH, et al. Preclinical development and characterisation of 99mTc-NM-01 for SPECT/CT imaging of human PD-L1. Am J Nucl Med Mol Imaging. 2021;11(3):154–66.

CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Cao M, Wu Y, Malih S, Xu D, Yang E, et al. Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers. J Immunother Cancer. 2024;12(4):e008794.

Article  PubMed  PubMed Central  Google Scholar 

Ma X, Zhou X, Hu B, Li X, Yao M, Li L, et al. Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging. Eur J Nucl Med Mol Imaging. 2023;50(13):3838–50.

Article  CAS  PubMed  Google Scholar 

Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, et al. First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung cancer patients. J Nucl Med. 2022;63(4):536–42.

Article